NVS — NOVARTIS AG catalysts

Name: Bio Catalyst Calendar — source-anchored biotech/pharma catalyst dates
Creator: Bio Catalyst Calendar
License: https://www.usa.gov/government-works

14 verified catalyst event(s) for NOVARTIS AG (ticker NVS). Each is linked to its official source. Verified as of 2026-11-04.

Next verified catalyst

2026-11-05 — Pediatric Long-Term Follow-up and Rollover Study · official source ↗

Upcoming

Date	Event	Company	Drug	Official source & verification
2026-11-05 in 1d ESTIMATED	READOUT Pediatric Long-Term Follow-up and Rollover Study Phase 4 · Diffuse Astrocytoma, Anaplastic Astrocytoma	NVS NOVARTIS AG	dabrafenib, trametinib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-12-14 in 1mo ESTIMATED	READOUT Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moder Phase 2 · Metastatic Castration-Resistant Prostate Cancer (mCRPC)	NVS NOVARTIS AG	AAA617, 68Ga-PSMA-11	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-12-23 in 2mo ESTIMATED	READOUT A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients Phase 2 · Prostatic Neoplasm	NVS NOVARTIS AG	AAA617, AAA517, Piflufolastat F 18, ARPI	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-12-30 in 2mo ESTIMATED	READOUT Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients Phase 3 · Tuberous Sclerosis Complex	NVS NOVARTIS AG	everolimus	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-12-30 in 2mo ESTIMATED	READOUT Iptacopan in Patients With ANCA Associated Vasculitis Phase 2 · Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis	NVS NOVARTIS AG	Iptacopan, Rituximab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01-25 in 3mo ESTIMATED	READOUT Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C M Phase 1/2 · KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung	NVS NOVARTIS AG	JDQ443, TNO155, tislelizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01-29 in 3mo ESTIMATED	READOUT Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvest Phase 2 · Breast Neoplasms	NVS NOVARTIS AG	Alpelisib, Fulvestrant	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01-29 in 3mo ESTIMATED	READOUT Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy. Phase 3 · C3G	NVS NOVARTIS AG	iptacopan	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-02-01 in 3mo ESTIMATED	READOUT Ribociclib (LEE011) Rollover Study for Continued Access Phase 2 · Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies	NVS NOVARTIS AG	LEE011	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-02-02 in 3mo ESTIMATED	READOUT Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Phase 2 · Melanoma	NVS NOVARTIS AG	LXH254, LTT462, Trametinib, Ribociclib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-02-22 in 4mo ESTIMATED	READOUT A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Time Phase 3 · Chronic Spontaneous Urticaria (CSU)	NVS NOVARTIS AG	Remibrutinib, Remibrutinib matching plac	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-02-26 in 4mo ESTIMATED	READOUT Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer Phase 1/2 · Breast Cancer	NVS NOVARTIS AG	LEE011, Letrozole, BYL719	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-02-26 in 4mo ESTIMATED	READOUT Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Ma Phase 3 · Advanced HER2+Breast Cancer	NVS NOVARTIS AG	Alpelisib, Alpelisib matching Placebo, T	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change

Past

Date	Event	Company	Drug	Official source & verification
2026-10-28 7d ago CONFIRMED	APPROVED PIQRAY	NVS NOVARTIS AG	PIQRAY	openFDA (drugsfda) ↗ ✓ Source-checked 2026-11-04 Actual/recorded date